I. INTRODUCTION
Cosmetic neurocognitive enhancement is the use of prescription stimulant drugs to enhance cognitive functions such as attention, concentration, and memory beyond normal limits in healthy people. 1 Interest in cosmetic neurocognitive enhancement has grown as treatments to improve cognition in individuals who suffer from illnesses that impact cognition have become more prevalent, safe, and effective. 2 Painted partly as self-improvement and partly as disease prevention, the idea that a person could be better than well by chemically manipulating the brain captivates the imagination. 3 Also sometimes called brain doping, 4 cosmetic prescribing, or wish-fulfilling medicine, the prescription medications most commonly requested for cosmetic purposes are stimulant medications regulated as Schedule II controlled substances such as methylphenidate (e.g. Ritalin and Concerta) and dextroamphetamine (e.g. Adderall and the prodrug Vyvanse). 5 The place of cosmetic neurocognitive enhancement in health care is controversial. Traditional definitions of health care stress the goals of diagnosis and treatment of the ill. Using this definition, cosmetic neurocognitive enhancement would not be considered health care because the requestor is not ill or disabled. However, the World Health Organization (WHO) has much broader definitions of health and health care 6 that would easily encompass the practice of cosmetic neurocognitive enhancement if the practice may be defined as the prescription of medication for promotion, maintenance, or restoration of the mental or social well being of the individual.
Similar to professional opinion, popular opinion is divided on the legitimacy of both the request for cosmetic neurocognitive enhancement and the provider response to the request. Some seekers of cosmetic neurocognitive enhancement are "early adopters" of a "successful" technology, 7 and portrayed as earnest students trying to weather an educational system that does not meet their individual learning needs. 8 A slightly less complimentary term, requestors of neurocognitive enhancement are sometimes referred to as "non-medical" users of highly regulated controlled substances. At the most pejorative end of the spectrum, some authors characterize all users of stimulants for cosmetic neurocognitive enhancement as addicted to the substances and/or guilty of "cheating." Providers are also portrayed at the extremes in the popular media. Providers who do not offer or provide cosmetic neurocognitive enhancement seem unfeeling, egotistical, paternalistic, and rigid. When providers do prescribe medications for cosmetic enhancement purposes (i.e. without clear evidence of illness), commentators characterize them as pawns of drug companies, medicalizing the human plight, ignorant of side effect, overly idealistic about benefits of drugs, and/or contributing to the problems of drug addiction and diversion.
In the sections that follow, I argue that the definition and scope of health care allows for the practice of cosmetic neurocognitive enhancement, that there is great variability in the population defined as well, and that sufficient indeterminacy exists so that a more nuanced view of cosmetic neurocognitive enhancement is necessary to inform policy and practice. Such a view respects the autonomy of both providers and patients, while balancing provider responsibilities such as beneficence, non-maleficence, and social justice. I then review drivers of patient requests for enhancement and physician experience with requests prior to concluding with a model practice guideline. I constrain the discussion to currently available medication because the assessment of risks and benefits of medication should be driven by the best empiric evidence available. 9 
II. NEUROCOGNITIVE ENHANCEMENT IN HEALTH CARE
Although some definitions of health care revolve around the prevention and treatment of disease, 10 the WHO takes a broader view of health, equating it with optimal well- being. 11 With only 17% of individuals functioning optimally, 12 health care activities are applicable to 83% of the population. In addition to the correction of abnormal bodily function to relieve symptoms, mental, emotional, and social factors are all considered equally important in this definition.
Other definitions of health emphasize the capacity of the individual to self-manage and adapt to the environment. 13 Cosmetic neurocognitive enhancement represents one way in which an otherwise well individual may choose to adapt to a challenging environment through the use of the services of a health care provider. From an ethical perspective, utility arguments favor cosmetic practices, 14 placing high value on the self-maintenance of health, enhancement of self-esteem, and improved social functioning as potential goods meriting inclusion of cosmetic enhancement as a health care activity.
From a practical standpoint, the care of the well is far from remote to the practice of health care. Medical providers hear patient requests for enhancement in consultation rooms across the United States every day with over half of providers receiving monthly requests for enhancement and more than 10% receiving daily enhancement requests. 15 In addition to hearing requests for enhancements, providers offer enhancements to patients. Approximately one third of providers offer enhancements to patients on at least a monthly basis and over 7% offer enhancements to patients on a daily basis. Cosmetic surgery is an example of health care offered to the well for the purpose of enhancement. Both cosmetic neurocognitive enhancement and cosmetic surgery alter the body of someone without known illness, despite risk of significant side effects. 17 Both have personal satisfaction as an unclear and difficult-to-measure endpoint. And both involve the use of limited resources for cosmetic enhancement despite significant ongoing need for restorative and rehabilitative services. 18 When effective, both processes tend to confer social advantage and thus potentially widen the gap between the enhanced and unenhanced. Similar to cosmetic surgery, third party payment for cosmetic neurocognitive enhancement is unlikely, so the resource is limited to individuals able to pay for it.
In some ways, however, the practice of cosmetic neurocognitive enhancement is more complicated and less certain than physical enhancement. Individuals requesting cosmetic neurocognitive enhancement are likely to feel stressed and dysphoric at the time of presentation, 19 which is a well-known risk factor for poor outcomes following cosmetic procedures.
In contrast, individuals usually deemed candidates for cosmetic procedures are "healthy individuals with a positive outlook and realistic expectations." 20 Other people at risk for a poor outcome following a cosmetic procedure include those with unrealistic expectations of the intervention, who view altering the body as "fixing" a life problem. In the case of neurocognitive enhancement, all requests involve a perceived need by the requestor to "fix" a mismatch between the cognitive demands imposed by the environment and the 17 Cosmetic surgery is the reshaping "of normal structures of the body in order to improve appearance and self-esteem." Cosmetic Procedures, AM. SOC'Y PLASTIC SURGEONS, http://www.plasticsurgery.org /cosmetic-procedures.html, archived at http://perma.cc/N8ZD-GQE2 (last visited May 20, 2015). 18 Chatterjee, Cosmetic Neurology, supra note 2, at 129-37. 19 Genevieve Verdi et al., Non-Medical Prescription Stimulant Use in Graduate Students Relationship With Academic Self-Efficacy and Psychological Variables, J. ATTENTION DISORDERS (Apr. 22, 2014) . 20 Cosmetic Procedures, supra note 14.
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resources possessed by the individual. Poor outcomes are then more likely because requestors are so focused on the goal that they almost invariably inflate potential benefit and minimize risk. 21 The effectiveness of most cosmetic surgery is measurable in physical and objective terms, while satisfaction with that change is more subjective. However, the effectiveness of cosmetic neurocognitive enhancement is only measured by subjective impressions of changes in cognition and the associated sense of satisfaction, all which is highly subjective and reliant upon the mood of the person evaluating the past experience at the time the person is asked to reflect on it.
While most cosmetic surgery involves a one-time procedure of greater risk than taking a prescribed stimulant as directed, cosmetic neurocognitive enhancement involves chronic treatment with drugs with unclear chronic effects. The brain is the most poorly understood organ in the body and brain pathways are highly interconnected so unintended effects may occur in an unpredictable fashion. Stimulants intended to improve cognition, for example, may also induce mood changes, irritability, anxiety, impulsivity and problems with reality testing. In addition to the direct risks of the individual medications, altering the brain likely also impacts the person's perception of self, others, and the intervention. At the extreme, the substance may potentiate vulnerability for addiction in the user such that the user values drug effects over social and occupational activities and relationships.
Strategies to optimize response and reduce risk at the individual level are equally relevant for cosmetic surgery and cosmetic neurocognitive enhancement. These include setting stable healthy habits as a precondition of cosmetic treatment, treating diagnosable conditions before moving to cosmetic enhancements, ensuring sufficient resources to maximize compliance with recommendations, and requiring financial accountability.
INDIANA HEALTH LAW REVIEW Vol. 12:2
At the societal level, cosmetic neurocognitive enhancement clearly poses more challenges than cosmetic surgery. Prescription drug abuse is a major public health problem and problematic use of stimulants is rising in all adult populations. 22 Personal misuse of medications may result in increased health care utilization and cost due to accidents and other complications in the individual who escalates dose and uses prescribed stimulants with other substances. Harm to others may occur when the individual does not properly store or dispose of medications, or diverts them to individuals to whom they were not prescribed. Sixty-one percent of college students diagnosed with attention deficit hyperactivity disorder (ADHD), a condition typically treated with prescribed stimulant medications, reported diverting stimulant medications. 23 Diversion may be more common in non-medical users of stimulant medications who require low doses on an intermittent basis in order to achieve the desired effects. 24 While the diversion of stimulant medications in the United States is a problem, the United States is by far the leading supplier of stimulants worldwide and it is unlikely that the global amphetamine issue can be addressed while stimulant production and consumption is increasing. 25 Up to 90% of the amphetamines sold through illicit means for recreational use are products of U.S. pharmaceutical firms, and half of the nation's illicit stimulant users consume pharmaceutical amphetamines only. 26 Although amphetamines were over the counter medications (OTCs) for forty years, and have been increasingly popular prescribed drugs, recognition of harms to public health resulted in an international resolution calling for the development of less risky substances capable of producing the same therapeutic benefit. 27 Manufacturers have made progress in producing less divertible alternative forms of stimulant medications such as patches and longacting formulations, an effective stimulant medication without some addiction liability does not yet exist. It is therefore incumbent on the provider to use the lowest possible dose, for the shortest possible time, with regular follow-up for the duration of medication provision to mitigate both individual and societal harm.
III. REQUESTS
The drives for wellness and enhancement are not new. 28 Human beings have attempted to improve and adapt for centuries. In this section I explore some of the recent drivers for requests for cosmetic neurocognitive enhancement and the expectations of requestors.
A. Neuromyths Facilitating Requests
There are a number of myths about brain structure and function that facilitate undue faith in cosmetic 29 People believe that intelligence is innate and immutable; 30 consequently, if they evaluate their own performances as suboptimal they use stimulants in the service of changing their destinies. Of those who consider that the brain is changeable, many people believe that the brain is a muscle, and that thinking builds brain cells so, the mythical analogy goes, thinking "more" or "faster" must somehow be good for the brain like aerobic exercise is good for the body.
Then, there is the popular culture belief that the brain is full of unused circuits and that our minds are limitless if we can but access the usually inaccessible areas. 31 In addition to the neuromyths mentioned above that are conducive to efficacy beliefs, other neuromyths cause people to minimize risk. Some neuromyths, for example, posit that the brain is modular, like a computer, leading people to believe that it is possible to affect one aspect of brain function without affecting others.
Add to this intuitive appeal the increasing reports in the media that stimulant medications are safe 32 and effective in enhancing complex problem solving and overall cognition, 33 the increase in demand and use is not surprising. A task for the provider is to identify and correct these misperceptions Contributing to neuromyths in popular culture that would make cosmetic neurocognitive enhancement desirable and seemingly attainable, the products used are also familiar to people due to the increasing frequency with which stimulants have been prescribed in recent years. There is not doubt that DTCA increases the number of requests for medications that patients bring to their providers and no doubt that the practice results in more prescriptions being written by providers. As the result of successful awareness campaigns and marketing, the use of prescription of stimulants increased exponentially and that increase is associated with increased non-medical use. 34 Amphetamines and other stimulant drugs have been used for more than 100 years for the treatment of impaired alertness, attention, and concentration. The products were first sold as OTC elixirs, and later as prescription products. Beginning twenty to thirty years ago, the regulatory environment became favorable for direct-to-consumer advertising (DTCA) of prescription products by pharmaceutical companies that, prior to that time, directed most advertising to prescribing providers. In 1999 the pharmaceutical industry launched the first DTCA campaign for stimulant drugs to treat children and other stimulant manufacturers followed suit in the two years that followed. The advertisements were typically lifestyle-based advertisements portraying ideal family life with the inference that such was possible if the parent treated the child's behavioral problems with prescribed substance. Soon thereafter the market became increasingly competitive with more companies and claims entering the market place.
In addition to raising awareness of treatable conditions, advertisements sometimes blur the boundaries between symptoms of normal function and those indicative of illness or disease, by emphasizing convenience, minimizing risk, overstating efficacy, and broadening indications, despite significant regulatory prohibitions. 35 It was not until 2006 that the FDA ordered a black box warning placed on stimulants for cardiovascular risk. This act quelled the DTCA of stimulants to some extent. By this time, however, the influence of the advertising in the marketplace had already been felt.
Importantly, the Food and Drug Administration (FDA) cannot require drug companies to submit advertisements for approval prior to marketing. As a result, members of the public may see advertisements that violate regulatory standards for variable periods of time prior to FDA review. During this interval, the individual viewing the advertisement will have no assistance in deducing whether the advertisement includes false or misleading information. 36 Once a deceptive advertisement is discovered, the FDA is empowered to send a letter to the manufacturer requesting that the company remove the advertisement or publish a corrective advertisement. In more egregious cases, the FDA has the discretion to issue warning letters, seek an injunction, or bring criminal action against a pharmaceutical company.
These actions, however, take time and there is also no particular requirement that the retraction or correction be displayed as prominently as the misleading advertisement. By the time the FDA acts, much harm has potentially been done. In the realm of cosmetic neurocognitive enhancement, people frequently cite goals of performing tasks better, working harder and optimizing personal achievement. Though people seeking stimulant medications believe that enhancing attention, concentration and task persistence will lead inevitably to these goals, this is not necessarily the case. 38 Some users believe that they suffer from undiagnosed ADHD and seek stimulants as the appropriate treatment for their self-diagnosed disorder outside a formal medical evaluation. 39 Others believe that because the primary motivation to use stimulants on a cosmetic basis is noble (i.e. to excel and assist others in excelling in the case of distribution) the use is more appropriate than in circumstances in which the primary motivation is to become intoxicated or euphoric. 40 Individuals 43 Individuals pursuing neurocognitive enhancement are generally not interested in altering traits they view as identifying or core personality characteristics such as mood and self-control as either direct effects or side effects of neurocognitive enhancement. 44 The reality, however, of brain manipulation is that changing one aspect of experience will doubtless change other aspects because the brain has a relatively small number of pathways that are used in different ways at different times for different things. The enterprise of cosmetic neurocognitive enhancement is all about trade offs, and owing to the biological reality of the connectome, will likely remain so for the foreseeable future. 45 For some users the trade off may be more favorable than for others, but users must understand there will be a trade off. 46 Attempts to distinguish cosmetic neurocognitive enhancement from substance misuse or addiction have largely demonstrated more similarities among, than differences between, stimulant users identifying academic goals and those espousing recreational goals for their use. 47 From a personality perspective, users of stimulants for cosmetic neurocognitive enhancement were more impulsive, less prosocial, less empathic, and more strategic and instrumental in their approach to life circumstances compared to individuals that did not use stimulants. 48 Those using cosmetic neurocognitive enhancement were more likely to associate stimulant use with recreation, report exaggerated well being, 49 abuse other substances (e.g. alcohol, marijuana, cocaine, ecstasy), and engage in risky activities. 50 Users of cosmetic neurocognitive enhancement failed to achieve objective long-term academic benefit despite report of short-term gains in self-perceived 52 It may well be that stimulants exert their primary enhancement effects on the emotions of users, as opposed to the cognition of users. 53 The moniker of "smart drug" may in fact conceal the degree to which the alteration sought is a mood alteration clothed in the language of intellect and achievement. Purposeful deception of physicians to obtain prescription stimulants may be more common than generally believed, 54 but continues to represent a minority of interactions with providers. 55 Users of stimulants for cosmetic neurocognitive enhancement are more likely to have antisocial features, which may increase the risk for purposeful deception of others. 56 Particularly among young adults, males, and individuals at the low and high extremes of income were more likely to report attempts to deceive physicians, as were young people who reported abusing recreational substances and those identified as lesbian-gay-bisexualtransgendered. 57 Several commentators have observed that prescribers are particularly easy to deceive, 58 and symptoms of disorders for which stimulants are prescribed are easy to feign. 59 The tactics identified by individuals deceiving clinicians include memorizing symptoms of ADHD and responding in deceptive ways on ADHD screening questions, writing things on their hands or displaying other signs of disorganization characteristic of ADHD, and complaining of improving but persistent symptoms to accomplish dose escalation that would lead to a sufficient supply of stimulant for the index "patient" and those to whom he or she may divert it. 60
IV. RESPONSES: PROVIDER ISSUES
Providers have varying levels of comfort with patient requests for enhancement and respond to these requests in a variety ways.
Many providers grant requests for enhancement and offer patients enhancements, though there is a significant minority that rejects enhancement of any kind as outside the practice of medicine. 61 
A. Models of Provider-Patient Interactions
How the provider understands the patient relationship is a significant variable in the response to patient requests. The traditional biomedical model is one in which providers rely on paternalism and objective data to guide their interactions with ill patients.
In this model, the responsibilities for diagnosis, treatment selection, treatment monitoring, and treatment goals all reside with the beneficent professional acting in his patient's best interest. The patient, in this model, offers his symptoms to the provider and accepts the treatment prescribed. The assumption in the biomedical model is that the patient and provider share amelioration of illness as the goal and both provider and patient will place high value on the symptomfree state. The biomedical model frequently works well with older, ill, distressed, and less-educated patients, 63 pursuing traditional treatments and treatment goals for a mutually identified disease state.
Traditional biomedical providers typically derive authority from the greater biomedical knowledge they possess and place a high level of confidence in evidencebased practices. Evidence-based medicine emphasizes the published literature as the primary source of credible information and authority. 64 Technical information offered to patients by biomedical providers will be informed by a combination of evidence from the professional literature, professional experience, and personal values. Cosmetic neurocognitive enhancement will succeed in the biomedical model typically used by traditional providers only when evidence from groups of similarly situated subjects demonstrates that there is known and discernible benefit that outweighs known risk. By contrast, most patients who seek cosmetic neurocognitive enhancement will be demographically different from those who prefer a traditional biomedical approach. Younger, healthier, and more highly educated patients will tend to prefer provider interactions that fall on the spectrum of informed choice 66 and shared decisionmaking models. 67 Although perspectives from traditional biomedical, informed choice and shared decision-making models are not mutually exclusive, they do have different centers of control, rely on different sources of authority, and prioritize different outcomes. 68 In traditional biomedical models, the provider makes the diagnosis, decides on treatment, and gives the patient information on the treatment and its risks, with some acknowledgment of alternatives. In informed choice models, the provider still sets the goals of treatment, but offers information without a specific recommendation to a more active patient considering treatments. In shared decisionmaking models, the provider offers information specific to the patient's stated goals and objectives with as little bias as possible and without any particular recommendation.
In informed choice and shared decision-making models, the provider's goal is to understand the patient's experience, wishes, and needs for the encounter from a broader biopsychosocial perspective, consistent with the definition of health care put forward by the WHO. The provider focuses on the patient's subjective need as the indication for the intervention, without relying on the presence of an illness as the threshold for providing a treatment intervention. The provider using a patient-centered frame of reference will likely be more comfortable with using the patient's opinion of the intervention as a viable justification for the intervention and for the evaluation of the effectiveness of 
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Vol. 12:2 the intervention. Providers operating in this frame may, for instance, go beyond responding to patient requests for cosmetic enhancement to offering the patient a cosmetic enhancement on a regular basis. 69 In most studies, patient satisfaction was associated with the more patient-centered approaches to the providerpatient relationship, specifically with provider attention to patient concerns and specific information about patient concerns from the provider. 70 Although outcomes among satisfied patients are difficult to assess, 71 compliance with provider recommendations appears highest among satisfied patients. 72 Discord between provider-and patient-centric models appears greatest when the provider does not value the patient's goal, believe that the available evidence supports the patient's expected benefit, or agree with the patient's assessment of risk. 73 For providers choosing to offer cosmetic neurocognitive enhancement to their patients, a shared decision-making model is most likely to be constructive in both assessing areas of functional change and in maximizing the compliance necessary to minimize individual and societal risks associated cosmetic neurocognitive enhancement. 
B. Provider Attitudes About Enhancement
Regardless of orientation of the provider to the providerpatient relationship, providers are generally risk-adverse. 74 The combination of unclear benefit and significant safety concerns contribute to discomfort in prescribing cosmetic neurocognitive enhancement. 75 Providers distrust safety claims about stimulants with good reason. Pemoline, for example, was a stimulant medication on the market for twenty-five years before concerns about liver injury became apparent and a black box warning was added to the labeling. It was then removed from the market five years later. 76 As a second example, the health risks of fenfluramine came to light after twenty-five years of market presence, when combined with phentermine (a stimulant) that had been on the market for almost forty years. Use of the combination product Fen-Phen for rapid weight loss has resulted in billions of dollars in litigation costs, medical surveillance, and damage awards. 77 After experiences such as these, providers will generally favor identifying an existing target symptom or sign of disability to merit the risk of prescribing stimulant medications. 74 In addition to ambivalence about safety and risk, providers are also ambivalent about access to cosmetic neurocognitive enhancement. Most providers believe that enhancement should be equally available to all people, 78 yet providers do not believe that third-party payers should cover enhancements. 79 They tend to view younger patients as not needing stimulant drugs and having sufficient nonpharmacological options for obtaining the same goals. 80 Providers were most comfortable prescribing to older patients to improve overall health, daily living, and support personal efficacy, 81 a finding that is concerning given the rate of misuse among people of advanced age 82 and the potential for drug interactions in those older adults receiving multiple medications.
When asked directly about enhancement, providers believed that enhancements could help people be happier, and identified subjective suffering, social pressures, and occupational problems as important factors.
Higher provider comfort with prescribing enhancement has been associated with older provider age, male gender, minority race, and high frequencies of patient requests for enhancement. 83 Recalling that DTCA tends to lead to more requests for medications, and applying now the notion that providers who hear more requests tend to be receptive to granting those requests, the impact of stimulant marketing is felt by both providers as well as patients. Additionally, some providers will have personal experience with cosmetic neurocognitive enhancement that will likely inform their recommendations to patients. One in five medical students use cosmetic neurocognitive enhancement, 84 and most plan to continue use after graduation. 85 The predicted continuation is bourn out by studies of practitioners demonstrating that a similar percentage report using stimulants solely for cognitive enhancement on at least one occasion, usually in association with environmental pressures. 86 These personal experiences may facilitate comfort with the practice of cosmetic neurocognitive enhancement. I.e., approved uses are recognized by the FDA as the only legitimate intended uses for the purposes of promotion and labeling.
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Vol. 12:2 licensed providers are not constrained from using medications for conditions other than those outlined in the FDA approved uses. 88 Off-label prescribing is common 89 and very much in the mainstream of medical practice. 90 There are, however, some responsibilities incumbent on the provider who undertakes this practice. The provider must base the off-label drug use on sound medical judgment and firm scientific rationale. 91 The provider must also thoroughly document the intervention, and obtain adequate informed consent. Even with these necessary steps, liability for off-label prescribing is a provider risk worthy of consideration and management through thorough documentation and peer consultation.
Proponents of off-label prescribing typically also favor allowing pharmaceutical companies to detail providers on off-label uses. When looking at established interventions and their indications, the professional literature is adequate to inform the provider. However, when either the drug or the indication is novel, the peer-reviewed literature will be lacking. Presumably the pharmaceutical company that developed a new agent will have the most data about new products and could make high-quality information from preclinical trials available to providers contemplating offlabel use. This would then allow the provider could discharge his above-mentioned responsibility to have thoroughly researched the agent prior to prescribing it. Implicit in this point of view is a high level of confidence in the ability of the provider to differentiate factual information from persuasive marketing and this confidence is frequently unmerited. 92 One possible way to create new sources of information on which providers could rely would be the establishment of efficacy and side-effect reporting schemes for off-label drug uses. This would provide a way for providers using cosmetic neurocognitive enhancement to communicate with one another and standardize some level of peer consultation. It is a potential way to create a source of information to which providers could turn to learn about novel agents, novel uses of established agents, and side effects from prescribed doses. While there are risks such as bias and incorrect inference inherent in this kind of informal research, access to data beyond the provider's individual professional experience could combat arguments that off-label prescribing is uniformly uninformed and wasteful. 93 D. Currently Available Enhancing Drugs
Schedule II Drugs
The most commonly used (and abused) drugs for neurocognitive enhancement are the Schedule II prescription amphetamines and methylphenidate. Generic names include methylphenidate, desmethylphenidate, detroamphetamine, and lisdexamphetamine. Trade names of some of these drugs include Adderall, Dexedrine, Ritalin, Concerta, Vyvanse, and Focalin. Street names include skittles, smarties, crosses, speed, and uppers. Sometimes 92 A supposition that is not true. Not only are providers influenced by ads, they frequently underestimate the degree to which they are influenced. This literature is reviewed elsewhere. 
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INDIANA HEALTH LAW REVIEW Vol. 12:2 these medications are erroneously described as universally effective for adult ADHD and universally enhancing. In fact, the evidence is decidedly more mixed. 94 Amphetamines and methylphenidate work by prolonging the action of dopamine and norepinephrine, resulting in activation of nerve cells in reward and executive function pathways, with a net result of improving focus, wakefulness, and concentration.
Short-term effects of relatively low oral doses include increased energy, alertness, and goal-directed activity, but sometimes come with the cost of increased anxiety and dysphoria with decreased multi-task coordination, cognitive flexibility, selfmonitoring, 95 and neural plasticity. 96 Other side effects associated with stimulant use include an unrealistic optimism, inflated sense of well-being, and inflated sense of ability. 97 Those taking non-medical stimulants perceive themselves as performing significantly better than their peers, despite the objective indicators to the contrary. 98 stimulants engaged in more speeding, were more impatient, exhibited diminished divided attention, and failed to stop appropriately. 99 Though these stimulants have complex effects on internal experience and motivation, there is no objective evidence to suggest that critical judgment, wisdom, generalized intelligence, competence, or overall achievement improve when taking stimulants 100 notwithstanding folk psychology and media portrayals. 101 There is little evidence to suggest that stimulants exert the same effects in individuals of high intelligence and normal cognitive ability than they do in cognitively impaired populations. 102 In a meta-analysis of studies of methylphenidate, the data "provide no consistent evidence for neuroenhancement effects." 103 Turning from efficacy to safety, data suggest that users of cosmetic neurocognitive enhancement reported side of effects during non-medical use of stimulants including anorexia (68.2% of non-medical users), insomnia (54. 112 improved working memory, more sustained attention, 113 and improved cognitive flexibility were noted among modafinil subjects when compared to similarly sleepdeprived controls. 114 Effects of modafinil are also similar to amphetamines in non-sleep deprived individuals, particularly at higher doses. 115 When compared to amphetamines and caffeine, modafinil exerts similar effects on wakefulness and vigilance, 116 but does not improve complex decisionmaking. 117 Although individuals with prior drug abuse report feeling intoxicated, non-sleep deprived individuals without a history of substance abuse did not. 118 In the most recent systematic review and meta-analysis of the available data on modafinil, researchers concluded that the literature supported the idea that modafinil improved attention in 110 
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INDIANA HEALTH LAW REVIEW Vol. 12:2 non-sleep deprived individuals but was not associated with improvements in other cognitive abilities such as task accuracy and timing. 119 Although modafinil is a popular study drug in Europe, and has been tested as an alternative to d-amphetamine as a wakefulness-promoting agent, 120 use in the United States may be limited by cost and availability. Although its effects on neural plasticity are unknown, 121 Modafinil is not dissolvable in water and does not remain stable at high temperature, so it cannot be injected or snorted. These features may make it a viable choice for providers engaging in conversations with patients about cosmetic neurocognitive enhancement.
OTC Drugs
A number of OTC drugs, nutritional supplements, and foods promising cosmetic neurocognitive enhancement are available to consumers on an increasing basis. The OTC drug market is by far the largest drug distribution system in the United States and is steadily growing, providing at least limited access to health care for people who would not otherwise have it. 122 In addition to traditional OTCs, health care consumers reach for supplements and food products to address cognitive health concerns. Herbal supplements have shown steady growth and sales reached 5.6 billion dollars in 2012. 123 The global healthy food market is INDIANA HEALTH LAW REVIEW Vol. 12:2 monitoring that many providers will require to prevent harm. Health care consumers attempting to make decisions about cosmetic neurocognitive enhancement deserve clear information about benefits and risks.
To the extent that cosmetic neurocognitive enhancement is used to navigate difficult social situations, societies are free to make decisions to alter those situations. If educational systems have become so overburdened that classrooms are places of randomness and chaos then a different class structure may be called for, rather than an amphetamine prescription. If there is such a gap between the top schools or workplaces and the next available situation, then it is time to expand the number of favorable educational environments and jobs. If there is recognition that fatigue is associated with significant errors then there could be limits on the numbers of continuous hours that people in high demand and high risk situations are permitted work. And, it might be time to revisit the wisdom of swing shift work. Individuals, enhanced or not, should be exposed to a broader range of options that allow for both the ability to make a living and the opportunity to sleep adequately. Given that they are not, a place for cosmetic neurocognitive enhancement is a part of the landscape of choices that people have in coping with the less than optimal situations with which they are faced.
Public policies that discourage drug use in the work or educational environment tend to reduce the number of individuals reaching for cosmetic neurocognitive enhancement by prohibited substances, be they the cosmetic agents specifically or the substances of abuse that may occasion cosmetic use. Though some may be over-reaching, these policies are generally because of the significant overlap between non-medical users and individuals with substance use disorders, who tend to escalate dose and use many stimulant substances at the same time, 132 apparent increase in achievement. 133 In addition to policies that discourage drug use, effective screening for individuals at risk for substance dependence and time-limited trials of potentially addicting medications are ways to minimize this risk.
The increase in U.S. production of amphetamine stimulants has caused worldwide concern for control of illicit amphetamine production and distribution. Several commentators have noted that the worldwide amphetamine problem cannot be addressed until the prescription of amphetamine substances is curbed by restricting indications, limiting production, or developing alternatives to amphetamines. Though not completely without risk, sustained release and transdermal preparations likely decrease dose escalation and are less attractive agents for diversion.
Additionally drugs such as modafinil may represent a promising prototype for a non-amphetamine stimulant. Over time others will likely be developed, particularly if quotas remain in place or tighten.
V. RECOMMENDATIONS FOR PROVIDERS AND SYSTEMS
Cosmetic neurocognitive enhancement is not new. Human beings have been using substances to this end for centuries, and some of these substances require the participation of a health care provider.
Since many conditions in neurology and psychiatry are based on self report and subjective disability, the issue at this juncture is not whether or not "normal" individuals receive prescribed products for enhancement but involve the process necessary to use these agents safely and the costs associated with such use. 134 Neuroscientific advances in delineating likely drug
